Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Catequentinib (Primary) ; Toripalimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 10 Oct 2019 New trial record